(UHS) Universal Health - Overview
Stock: Acute Care, Behavioral Health, Outpatient Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.41% |
| Yield on Cost 5y | 0.62% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 56.3% |
| Payout Ratio | 5.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.9% |
| Relative Tail Risk | -6.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | 2.07 |
| Character TTM | |
|---|---|
| Beta | 0.640 |
| Beta Downside | 0.734 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.64% |
| CAGR/Max DD | 0.42 |
Description: UHS Universal Health January 02, 2026
Universal Health Services, Inc. (NYSE: UHS) operates a network of acute-care hospitals and outpatient/behavioral-health facilities across the United States, organized into Acute Care Hospital Services and Behavioral Health Care Services segments. Its sites deliver a full suite of services-including general and specialty surgery, obstetrics, emergency care, radiology, oncology, and pharmacy-while also offering commercial health-insurance and a range of back-office management functions such as central purchasing and physician recruitment. Founded in 1978 and headquartered in King of Prussia, PA, UHS is classified under the Health Care Facilities sub-industry.
Key performance indicators that analysts watch include: (1) FY 2024 revenue of approximately $13.2 billion, up ~5 % YoY, driven by higher admission volumes and price-inflation adjustments; (2) an occupancy rate that has stabilized around 78 % after pandemic-related swings, which is above the industry median of ~73 %; and (3) a cash-flow conversion rate exceeding 80 %, supporting its aggressive acquisition pipeline. Primary economic drivers for the sector are an aging U.S. population, increasing demand for behavioral-health services, and the impact of Medicare/Medicaid reimbursement reforms on profit margins.
For a deeper quantitative look, see the ValueRay analysis of UHS.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 1.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.48 > 1.0 |
| NWC/Revenue: 0.58% < 20% (prev 5.13%; Δ -4.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.95b > Net Income 1.38b |
| Net Debt (5.00b) to EBITDA (2.58b): 1.94 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.0m) vs 12m ago -4.58% < -2% |
| Gross Margin: 90.34% > 18% (prev 0.90%; Δ 8944 % > 0.5%) |
| Asset Turnover: 114.4% > 50% (prev 107.4%; Δ 7.02% > 0%) |
| Interest Coverage Ratio: 12.90 > 6 (EBITDA TTM 2.58b / Interest Expense TTM 153.5m) |
Altman Z'' 4.57
| A: 0.01 (Total Current Assets 3.26b - Total Current Liabilities 3.16b) / Total Assets 15.34b |
| B: 0.51 (Retained Earnings 7.87b / Total Assets 15.34b) |
| C: 0.13 (EBIT TTM 1.98b / Avg Total Assets 14.85b) |
| D: 1.87 (Book Value of Equity 15.04b / Total Liabilities 8.05b) |
| Altman-Z'' Score: 4.57 = AA |
Beneish M -2.98
| DSRI: 1.06 (Receivables 2.59b/2.21b, Revenue 16.99b/15.42b) |
| GMI: 0.99 (GM 90.34% / 89.78%) |
| AQI: 0.94 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.10 (Revenue 16.99b / 15.42b) |
| TATA: -0.04 (NI 1.38b - CFO 1.95b) / TA 15.34b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of UHS shares?
Over the past week, the price has changed by +8.60%, over one month by -1.43%, over three months by -3.38% and over the past year by +16.47%.
Is UHS a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UHS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 250.4 | 14.5% |
| Analysts Target Price | 250.4 | 14.5% |
| ValueRay Target Price | 235.7 | 7.9% |
UHS Fundamental Data Overview February 03, 2026
P/E Forward = 8.673
P/S = 0.7537
P/B = 1.7441
P/EG = 1.87
Revenue TTM = 16.99b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.58b USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 813.5m USD (from shortTermDebt, last quarter)
Debt = 5.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b USD (from netDebt column, last quarter)
Enterprise Value = 17.81b USD (12.81b + Debt 5.11b - CCE 112.9m)
Interest Coverage Ratio = 12.90 (Ebit TTM 1.98b / Interest Expense TTM 153.5m)
EV/FCF = 18.75x (Enterprise Value 17.81b / FCF TTM 949.6m)
FCF Yield = 5.33% (FCF TTM 949.6m / Enterprise Value 17.81b)
FCF Margin = 5.59% (FCF TTM 949.6m / Revenue TTM 16.99b)
Net Margin = 8.09% (Net Income TTM 1.38b / Revenue TTM 16.99b)
Gross Margin = 90.34% ((Revenue TTM 16.99b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 90.22%)
Tobins Q-Ratio = 1.16 (Enterprise Value 17.81b / Total Assets 15.34b)
Interest Expense / Debt = 0.75% (Interest Expense 38.4m / Debt 5.11b)
Taxrate = 23.70% (117.8m / 496.9m)
NOPAT = 1.51b (EBIT 1.98b * (1 - 23.70%))
Current Ratio = 1.03 (Total Current Assets 3.26b / Total Current Liabilities 3.16b)
Debt / Equity = 0.71 (Debt 5.11b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 1.94 (Net Debt 5.00b / EBITDA 2.58b)
Debt / FCF = 5.26 (Net Debt 5.00b / FCF TTM 949.6m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.26% (Net Income 1.38b / Total Assets 15.34b)
RoE = 19.85% (Net Income TTM 1.38b / Total Stockholder Equity 6.93b)
RoCE = 18.20% (EBIT 1.98b / Capital Employed (Equity 6.93b + L.T.Debt 3.95b))
RoIC = 13.11% (NOPAT 1.51b / Invested Capital 11.52b)
WACC = 6.07% (E(12.81b)/V(17.92b) * Re(8.27%) + D(5.11b)/V(17.92b) * Rd(0.75%) * (1-Tc(0.24)))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 87.81% ; FCFF base≈952.5m ; Y1≈1.17b ; Y5≈2.00b
Fair Price DCF = 905.2 (EV 55.00b - Net Debt 5.00b = Equity 50.00b / Shares 55.2m; r=6.07% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 11.74 | EPS CAGR: -42.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.55 | Revenue CAGR: 8.81% | SUE: 3.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.29 | Chg30d=-0.026 | Revisions Net=-1 | Analysts=10
EPS next Year (2026-12-31): EPS=23.39 | Chg30d=-0.114 | Revisions Net=-3 | Growth EPS=+7.4% | Growth Revenue=+5.0%